LMAT icon

LeMaitre Vascular

99.06 USD
+0.83
0.84%
At close Jan 17, 4:00 PM EST
After hours
99.06
+0.00
0.00%
1 day
0.84%
5 days
6.37%
1 month
8.94%
3 months
10.45%
6 months
14.55%
Year to date
8.30%
1 year
74.06%
5 years
168.67%
10 years
1,189.84%
 

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Employees: 630

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

171% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 17

80% more call options, than puts

Call options by funds: $483K | Put options by funds: $269K

13% more capital invested

Capital invested by funds: $1.73B [Q2] → $1.95B (+$222M) [Q3]

10% more funds holding

Funds holding: 261 [Q2] → 288 (+27) [Q3]

8% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 95

0.13% less ownership

Funds ownership: 93.5% [Q2] → 93.37% (-0.13%) [Q3]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$93
6%
downside
Avg. target
$93
6%
downside
High target
$93
6%
downside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Suraj Kalia
61% 1-year accuracy
14 / 23 met price target
6%downside
$93
Outperform
Reiterated
1 Nov 2024
Barrington Research
Michael Petusky
55% 1-year accuracy
38 / 69 met price target
6%downside
$93
Outperform
Maintained
1 Nov 2024

Financial journalist opinion

Positive
CNBC Television
3 weeks ago
Julie Biel shares her 2025 small cap picks
CNBC guest trader Julie Biel shares her 2025 small cap picks.
Julie Biel shares her 2025 small cap picks
Neutral
Zacks Investment Research
3 weeks ago
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport.
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
Neutral
GlobeNewsWire
1 month ago
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes.
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering
Neutral
CNBC Television
1 month ago
Final Trade: LMAT, GOOGL, IBM, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: LMAT, GOOGL, IBM, GILD
Positive
Zacks Investment Research
1 month ago
RMD vs. LMAT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks?
RMD vs. LMAT: Which Stock Is the Better Value Option?
Neutral
GlobeNewsWire
1 month ago
LeMaitre to Participate at Upcoming Investor Conferences in December
BURLINGTON, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in December.
LeMaitre to Participate at Upcoming Investor Conferences in December
Positive
Seeking Alpha
2 months ago
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth.
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Neutral
GlobeNewsWire
2 months ago
LeMaitre to Participate at Upcoming Investor Conferences in November
BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November.
LeMaitre to Participate at Upcoming Investor Conferences in November
Neutral
Seeking Alpha
2 months ago
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q3 2024 Earnings Conference Call October 33, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Suraj Kalia - Oppenheimer Rick Wise - Stifel Brett Fishbin - KeyBanc Jason Wittes - Roth Danny Stauder - Citizens JMP Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Ross Osborn - Cantor Fritzgerald Operator Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call.
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago.
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
Charts implemented using Lightweight Charts™